Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methoxyflurane versus standard breakthrough analgesia for movement-related pain during inpatient radiotherapy transport and positioning
ACTRN12606000073505Phase 4Not yet recruiting
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- May 2006
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of methoxyflurane and morphine in cancer pain (2 arms), sponsored by Peter MacCallum Cancer Centre. Primary endpoint: Difference in efficacy for controlling pain associated with movement and positioning during radiotherapy. Planned start May 2006; status: not yet recruiting.
02
Drugs
methoxyfluranemorphine
03
Conditions
cancer pain
Beyond the preview
Go deeper on ACTRN12606000073505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000073505.